T cell-mediated antibody-dependent cellular cytotoxicity provides a therapeutic approach for solid cancers.
The clinical success of chimeric antigen receptor T cells in treating hematological malignancies has highlighted the immense therapeutic potential of engineering T cells with synthetic receptors. However, the limited availability of tumor-specific antigens and the poor ability of T cells to infiltrate solid tumor cores...